C hronic hypoxia is a potent stimulus for pulmonary vasculature remodeling that progresses to pulmonary hypertension (PH).
C hronic hypoxia is a potent stimulus for pulmonary vasculature remodeling that progresses to pulmonary hypertension (PH). 1 Accumulating evidence indicates that endothelial dysfunction is an early and critical event in the onset and progression of PH which is marked by danger signal receptor-mediated reduction in nitric oxide (NO) production and an increase in reactive oxygen species (ROS) production. 2 Endothelial nitric oxide (eNOS) is a major target for the treatment of PH, and its activity is controlled by a plethora of factors such as caveolin-1, HSP90, Akt-dependent phosphorylation and Arg2 (arginase 2). Although studies seem to converge on the reduction of NO production with hypoxia, effects of hypoxia on eNOS expression are inconsistent. For example, pulmonary arteries isolated from rats with hypoxia-induced PH exhibited either unchanged or increased expression of eNOS mRNA and protein as compared with controls, and increased eNOS protein expression has correlated positively with the development of PH in humans. [2] [3] [4] [5] [6] Our laboratory has been focused on factors that regulate the function of eNOS, but do not necessarily alter its abundance. Arg2 is an enzyme that has been conclusively demonstrated to reciprocally regulate the production of eNOS-derived NO and endothelial function. [7] [8] [9] [10] Patients with PH have increased levels of lung HIF (hypoxia-inducible factor)-1α, 11, 12 and hypoxia has been demonstrated as a robust stimulus for Arg2 expression in pulmonary artery (PA) endothelial cells by a mechanism involving transcriptional input from HIF-2α. 13 Indeed, HIF-2α has recently been shown to be a key transcription factor (TF) regulating pathogenesis of PH. 14, 15 However, HIF-2α is apparently not the only regulator of Arg2 in lung endothelium during hypoxia, and can only partly account for hypoxia-induced increases in Arg2 (Krotova et al 14 ; Figure 5 ). These issues highlight the need for new targets in blood vessels for treatment or prevention of PH pathogenesis. 16 We have therefore taken a candidate approach to identify other important endothelial TFs that might regulate the expression of Arg2. The KLF (Kruppel-like factors) have been shown to be critical regulators of developmental and biological function in the vasculature and are dysregulated in the context of endothelial pathobiology. [17] [18] [19] [20] KLF2 and 4 are highly expressed in endothelial cells under laminar stress, but their expression is significantly reduced at branch points and other areas of turbulent flow. 21 Moreover, KLF2 and 4 are important transactivators of eNOS, thereby contributing to laminar shear stress-induced increases in NO production and endothelial protection. 22, 23 Further, they lead to the repression of cytokine genes and increase the expression of adhesion molecules that inhibit endothelial cell inflammation and endothelial dysfunction. Importantly, hemizygous gene deletion of KLF2 and the myeloid-specific KLF4 gene deletion lead to accelerated atherogenesis in ApoE −/− mice. 24, 25 However, the recent elegant demonstration of reduction in plaque stability with smooth muscle cell-specific conditional knockout of KLF4 raises a concern about the strategy of activating KLF4 to treat atherogenesis. 26 KLF15 is a member of the KLF family that has garnered significant attention recently for its protective role in vascular inflammation and atherogenesis, 27 proliferation and migration, 28 heart failure and aortic aneurysm formation, 29 and pressure-induced cardiac hypertrophy. 30 Although the importance of KLF15 is emerging in some cardiovascular diseases, the role of KLF15 in endothelial function is unknown.
At the outset of the current study, we aimed to determine the role of KLF15 in vascular endothelial function. We were intrigued by the almost complete loss of KLF15 expression in the cardiomyocytes of cardiomyocyte-specific ryanodine receptor type (tamoxifen-inducible) knockout mice, which has been shown to cause a hypoxia-like cellular state. 31 Hence, in the current study, we examined the role of KLF15 in controlling critical genes for vascular endothelial function in the context of hypoxia-induced pulmonary vascular disease.
Materials and Methods

Reagents
All experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee at The Johns Hopkins University School of Medicine. Rats were purchased from Jackson Laboratory. Unless otherwise stated, all reagents were obtained from Sigma. KLF15 siRNA was purchased from Qiagen. eNOS (sc-376542) and Arg2 (sc-20151) antibodies were purchased from Santa Cruz, KLF15 antibody was purchased from Novus Biologicals (NBP2-24635). Anti-HA antibody (cat number 11867423001) was purchased from Roche (now Sigma-Aldrich). Alexa Fluor 488 antiRat secondary antibody was purchased from Invitrogen (Catalog number A-11094). KLF15 flexitube siRNA number (SI04184537), number 9 (SI04299337) was purchased from Qiagen. Lipofectamine 2000 (Catalog number 11668027) was purchased from Life Technologies. Live/Dead Viability/Cytotoxicity kit for mammalian cells was purchased from Thermofisher Scientific (catalog number L3224).
Cell Culture
Human pulmonary microvascular endothelial cells (HPMEC) were maintained in endothelia medium culture medium (Science Cell Research Laboratories, Carlsbad, CA) according to the supplier's protocol. HPMEC were transfected using the Amaxa transfection system (Lonza). To subject cells to hypoxic environment, cell culture plates were inserted into hypoxic chambers, flushed with 5% CO 2 and 95% Nitrogen for 10 minutes and then incubated in regular cell culture incubation with 5% CO 2 .
RT-PCR and Real-Time PCR
Total RNA was extracted from HPMEC using Trizol and PureLink (Invitrogen). RNA was then reverse transcribed with oligo dT primers to obtain cDNA and quantitative real-time PCR (Applied Biosystems) was performed using SYBR Green Supermix mix (Applied Biosystems) whereas semiquantitative RT-PCR was performed using a conventional Biorad PCR machine and the following primer sets: Human Arg2: forward: 5′-GGG CCC TGA AGG CTG TAG-3′, reverse: 5′-AAT GGA GCC ACT GCC ATC-3′. Human KLF15: forward: CCA AAA GCA GCC ACC TCA AG, reverse: GAC ACT GGT ACG GCT TCA CA. Human KLF2: forward: 5′-CGG CAA GAC CTA CAC CAA GA-3′, reverse: 5′-GCA CAG ATG GCA CTG GAA TG-3′; and Human KLF4: forward: 5′-AAG CCA AAG AGG GGA AGA CG-3′, reverse: 5′-GCG AAT TTC CAT CCA CAG CC-3′.
Real-time PCR data are expressed as fold change, and is calculated as 2 −ΔΔCt . This is derived as follows: Delta Ct (ΔCt) means difference in Ct values between gene of interest (Arg2 in our case) and the housekeeping gene 18s; Delta Delta Ct (ΔΔCt) means difference in Delta Ct values between hypoxia and normoxia or GFP (green fluorescent protein) and KLF15 overexpression, and this is the fold change.
DNA Constructs and Adenoviruses
HA (YPYDVPDYA)-and FLAG (DYKDDDDK)-epitope-tagged KLF15 were constructed by PCR using untagged human KLF15 purchased from the Arizona State University plasmid repository as a template using and following primers: HA-KLF15-forward-5′-GGG CCC GGA TCC ATG TAC CCC TAC GAC GTG CCC GAC TAC GCC GTG GAC CAC TTA CTT-3′; HA-KLF15-reverse-5′GGG CCC CTC GAG CTA GTT CAC GGA GCG CAC GG-3′. One hundred thirty-five amino acids at KLF15 C-terminus corresponding to zinc-finger domain in KLF15 were truncated using following primers: forward: 5′-GGG CCC GAA TTC CTA AAT GCG CAC AAA CTT GGA GGG C-3′; reverse: 5′-GGG CCC GAA TTC CTA GTT CAC GGA GCG CAC GG-3′.
The PCR product was cloned into pcDNA3.1 using directional topo cloning (Invitrogen). Adenoviruses encoding HA-and FLAGtagged KLF15 was constructed by subcloning into entry PENTR1a vector using and restriction enzymes followed by LR recombination with destination vector PDEST. The HDAC2-PDEST DNA was 
Force Tension Myography
Rat PA was isolated and incubated in endothelia medium either in normoxic or hypoxic conditions for 24 hours similar to cell culture conditions. Post 24-hour PA was cleaned in ice-cold Krebs-Ringer bicarbonate solution containing the following (in mmol/L): 118.3 NaCl, 4.7 KCl, 1.6 CaCl 2 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 1.2 MgSO 4 , and 11.1 dextrose. The PA was immersed in a bath filled with constantly oxygenated Krebs buffer at 37°C. Equal size PA rings (2 mm) were mounted using a microscope, ensuring no damage to the smooth muscle or endothelium. One end of the PA rings was connected to a transducer, and the other to a micromanipulator. PA was passively stretched to an optimal resting tension using the micromanipulator, after which a dose of 60 mmol/L KCl was administered, and repeated after a wash with Krebs buffer. After these washes, all vessels were allowed to equilibrate for 20 to 30 minutes in the presence of indomethacin (3 μmol/L). Phenylephrine (1 μmol/L) was administered to induce vasoconstriction. Dose-dependent responses (1 nmol/L to 10 μmol/L), to the muscarinic agonist, ACH or to the nitric oxide donor, SNP, were then performed as necessary. The responses were repeated in the presence of inhibitors. Relaxation responses were calculated as a percentage of tension after preconstriction. Sigmoidal doseresponse curves were fitted to data with the minimum constrained to 0. Two to 4 rings were isolated from each animal and the number of animals in each group (n) was 6.
Human Arg2 Promoter Assay Using Luciferase Activity
Chromosomal DNA was prepared from HPMEC using Trizol reagent as per manufacturer's protocol (Life Sciences). Promoter fragments of Arg2 were amplified by PCR using genomic DNA isolated from human aortic endothelial cells and specific primer sets as follows: Arg2 promoter F: 5′-AAA CTC CTG ACC TCA GGT GA-3′, Arg2 promoter R: 5′-GCG GTT GGA AGC CGG GAG TG-3′. The PCR product was used as a template to further add XhoI and HIndIII sites to the 5′ and 3′ end respectively using following primers: Arg2 Xho-5′-GGG CCC CTC GAG AAA CTC CTG ACC TCA GGT GAT CCA CCT GCC TC-3′ and Arg2 HindIII-5′-GGG CCC AAG CTT GCG GTT GGA AGC CGG GAG TGA GCG CCA CCG CCC G-3′. These were cloned into the restriction sites for XhoI and HindIII on the pGL3-enhancer vector (Promega Co). HPMEC were transfected with the plasmids using Fugene 6 reagent (Roche Co), and luciferase activity was measured by Dual-luciferase reporter assay system (Promega Co). The luciferase activity was reported as relative luciferase units by dividing firefly luciferase activity by Renilla luciferase activity and normalized to protein concentration. TF binding consensus sequences in Arg2 promoter sequence were analyzed by using Ensembl, TRANSFAC database (http://www. gene-regulation.com/pub/databases.html#transfac) and MacVector software (Accelrys, San Diego, CA).
Immunoprecipitation and Western Blotting
After 48 hours of HPMEC cells transfection, cells were lysed in ice-cold RIPA lysis buffer consisting of 20 mmol/L Tris-HCl at PAH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% NP40, 1% sodium deoxycholate, 1 mmol/L Na 3 VO 4 , 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β-glycerophosphate, 1 μg/mL leupeptin, and a 1:1000 diluted protease inhibitor cocktail (Sigma). For immunoprecipitation studies, whole cell lysates were centrifuged at 14 000g and supernatants were precleared by incubation with Protein A/G-agarose beads for 2 hours at 4°C with rocking. Agarose beads were then pelleted by centrifugation at 1000g. FLAG-Arg2 in precleared lysates were immunoprecipitated by incubation overnight at 4°C with rocking after addition of anti-FLAG antibody (10 µL). Immune complexes were eluted in 2x SDS sample buffer by boiling for 5 minutes before loading into SDS-PAGE. Western blotting analysis was performed by transferring the SDS gel onto a PVDF membrane and visualized using secondary antibodies conjugated to alkaline phosphatases.
Arginase Activity Assay
HPMEC were lysed using RIPA buffer (50 mmol/L of Tris-HCl; PAH, 7.5; 0.1 mmol/L, EDTA; 0.1%, Triton X-100; and protease inhibitor), and centrifuged for 30 minutes at 14 000g at 4°C. Supernatant (50 μL [50-100 µg]) was added to 75 μL of 10 mmol/L MnCl 2 made in Tris-HCl (50 mmol/L; PAH, 7.5) and heat activated by incubating at 55°C to 60°C for 10 minutes. L-Arginine (50 μL) that was prepared in 300 mmol/L Tris-HCl, PAH 9.7 were then added to the activated cell lysates to achieve final concentrations of 150 mmol/L and incubated at 37°C for 3 hours with shaking. The reaction was stopped by adding 400 μL of an acid solution (H 2 SO 4 : H 3 PO 4 : H 2 O=1:3:7). For colorimetric determination of urea, α-isonitrosopropiophenone (25 μL, 9% in ethanol) was added and further heated at 100°C for 45 minutes. Samples were allowed to cool at room temperature in the dark for 10 minutes, and urea concentration was determined by measuring absorbance at 550 nm using a spectrophotometer.
Subcellular Localization
Subcellular localization of KLF15 in response to hypoxia was determined by immunofluorescence. Briefly, on conclusion of hypoxia, HPMECs were permeabilized for 2 minutes with 0.5% Triton X-100 (Sigma-Aldrich) in 4% paraformaldehyde solution. Cells were then fixed in 4% paraformaldehyde for 20 minutes at room temperature followed by 2 washes with PBS. Samples were incubated with anti-HA antibody (Sigma-Aldrich, rat, 1:100) in blocking buffer (0.1% BSA in Universal Buffer) for 1 hour at 37°C. Samples were then incubated in secondary antibody (Alexafluor 488 anti-rabbit secondary antibody, 1:100 dilution, Invitrogen) and DAPI for 1 hour at 37°C. Samples were subsequently mounted with FluorSave mounting medium (EMD Millipore). Images were acquired using Zeiss LSM 800 laser-scanning confocal microscope equipped with Zen 2.3 software (2011). April 2018
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using Magna ChIP kit from Millipore as per manufacturer's protocol. Briefly, Confluent HPMEC expressing HA-KLF15 were incubated with 1% formaldehyde at 37°C for 10 minutes to crosslink Histones and DNA. The crosslinked complexes were subjected to shearing with sonication and immunoprecipitated with anti-HA antibody. After reverse crosslinking, purified and immunoprecipitated DNA was amplified using real-time PCR and Arg2 promoter-specific primers: CHIP-A For: 5′-TTC AAT GAA CTG AAC AAG TAT G-3′, CHIP-A Rev: 5′-TAG GGC ACC GGT AAC CTA TG-3′; CHIP-B For: 5′-TTG GCC TTC TGG CGT CAG CG-3′, CHIP-B Rev: 5′-GCT CTG CAA GGC TGG GAC GTG-3′.
Measurements of Nitric Oxide Production
Nitric oxide production in the cell culture media was determined by measuring nitrite levels with a Sievers NO analyzer. Nitric oxide levels in HPMEC were also determined using DAF-DA as per manufacturer instructions (Life Sciences). Briefly, cells were loaded with DAF-DA (5 µmol/L) for 20 minutes and washed 3× with PBS and incubated for another 30 minutes in phenol-free media. Fluorescence was determined using a Nikon TE-200 epifluorescence microscope. Images were captured with a Rolera EMC2 camera (Q-Imaging, BC, Canada) with Velocity software (PerkinElmer, Lexington, MA).
Measurements of ROS Production
Luminol analog L-O12 32 as described previously and EPR was used to measure ROS. Briefly, HPMEC overexpressing either GFP or HA-KLF15 were incubated under normoxic or hypoxic conditions for 24 hours. Post 24 hours, cells were treated with 0.075 mL phosphate-buffered saline (PBS) containing 0.1 mmol/L diethylenetriaminepentaacetic acid (DTPA) and protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) at pH 7.4. The cells were scraped, kept on ice, and analyzed within 1 hour. Stock solutions of 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine hydrochloride (CMH; Enzo Life Sciences, Farmingdale, NY) were prepared daily in nitrogen purged 0.9% (wt/vol) NaCl, 25 g/L Chelex 100 (Bio-Rad) and 0.1 mmol/L DTPA, and kept on ice. 1 The samples were treated with 1 mmol/L CMH at RT for 10 minutes, transferred to 0.050 mL glass capillary tubes, and analyzed on a Bruker E-Scan (Billerica, MA) electron paramagnetic resonance spectrometer. Spectrometer settings were as follows: sweep width=100 G; microwave frequency=9.75 GHz; modulation amplitude=1 G; conversion time=5.12 ms; receiver gain=2×10 3 ; number of scans=16.
Stretching Protocol
HPMECs were uniaxially stretched (15%, 1 Hz) using a stretching apparatus (ST-140-10; STREX, Osaka, Japan) for 6 hours. Cell media were collected from the stretch chambers for nitrite measurements using Sievers.
Sugen-Hypoxia Protocol
Rats were subcutaneously injected with SU5416 (20 mg/kg) and placed in a chamber maintained at FiO 2 =10% for 21 days. Control normoxic rats remained next to the chamber to maintain consistent environmental factors. At day 21, rats were removed from hypoxia, anesthetized with pentobarbital via intraperitoneal injections and lungs were explanted. The lungs were instilled with 10% formalin, removed en bloc and fixed in formalin before embedding and sectioning. The sections were subjected to immunohistochemical staining using KLF15 antibody.
Statistics
All statistical analyses were performed using Prism 7 for Mac, by GraphPad Software Inc, and by Microsoft Excel version 14.1.3 statistical analysis software. The results were expressed as mean and SE (mean±SEM). One-way analysis of ANOVA and the Bonferroni post hoc test for multiple-comparison were used to compare all experimental data sets, groups, and pairs of data sets, respectively. A value of P<0.05 was considered statistically significant. Myograph data were analyzed using general linear model with group as a factor and dose as a repeated measure using STATA VERSION 15 software, STATA Corporation, College Station, TX. Post hoc tests were applied for each dose using linear combination based on this model.
Results
KLF15 Is Expressed in Quiescent HPMEC, and Regulates Expression of Arg2 and eNOS-Enzymes That Are Critical for Endothelial Function
Recent studies that were focused primarily on vascular smooth muscle cells suggested an important role for KLF15 in vascular injury, inflammation, and atherosclerosis. 28, 29, 33 We, therefore, investigated the role of KLF15 in the regulation of genes that affect pulmonary vascular endothelial function. We first determined whether KLF15 mRNA was expressed in HPMEC. As shown in Figure 1A , using RT-PCR we demonstrated that KLF15 mRNA is expressed in substantial quantities in HPMEC. These data provide the first evidence for the expression of KLF15 in endothelial cells. We compared KLF15 expression in human endothelial cells cultured from different vascular beds (pulmonary microvascular, aortas, and coronary artery) to expression in human aortic smooth muscle cells. As shown in Figure 1B , KLF15 was expressed at varying levels in endothelial cells isolated from all 3 endothelial populations. Cell lysates of ectopically expressed FLAG-KLF15 were used as a positive control for KLF15 expression. Interestingly, it seems that human aortic smooth muscle cells express KLF15 at much lower levels than endothelial cells ( Figure 1B) . We also measured and compared relative levels of KLF15 to KLF2 and KLF4-TFs that are well-studied in the context of endothelial function. 19 KLF15 expression was found to be significantly higher in HPMEC than that of either KLF4 or KLF2 ( Figure 1C ). As a TF and a regulatory protein, its expression level was however found to be lower than that of the highly abundant EC proteins and markers CD31 and VWF ( Figure I in the online-only Data Supplement). Arg2 and eNOS compete for L-arginine, and Arg2 reciprocally regulates eNOS and the production of NO that is protective for endothelium. 34 In the systemic circulation, Arg2 expression is enhanced during atherogenesis, resulting in endothelial dysfunction by uncoupling eNOS. 8, 35, 36 Transient overexpression of KLF15 in quiescent HPMEC robustly increased eNOS levels and almost completely obliterated Arg2 protein levels ( Figure 1D ). This effect was found to be dose-dependent (data not shown). Increased KLF15 expression also attenuated arginase activity in quiescent HPMEC and increased NO production ( Figure 1E and 1F, bottom) . Furthermore, the observed KLF15-mediated increase in nitric oxide production was enhanced when cells were subjected to physiological stretch in a pattern that mimicked human breathing parameters 37 as shown in Figure 1F , top. We next determined whether loss of KLF15 function in HPMEC has any effect on Arg2 levels. Using 2 different siRNAs (number 7, number 9) targeted to 2 different regions of KLF15 coding DNA sequence, we demonstrated that KLF15 knockdown resulted in 4-fold to 6-fold increase in Arg2 levels ( Figure 1G ).
KLF15 Is Decreased by Hypoxia in HPMEC
We exposed HPMEC to hypoxia (2% O 2 ) to test the effects of this stimulus on KLF15, and found that protein levels were markedly reduced, but that mRNA levels were unchanged ( abundance, despite the fact that hypoxia-induced increased Arg2 levels in these cells. This indicates that KLF15 sensitivity to hypoxia is unique to HPMEC (among the EC studied thus far; Figure V in the online-only Data Supplement). Using immunohistochemistry ( Figure 2C ) and Western blot ( Figure 2D ), we further demonstrated that KLF15 abundance is significantly reduced in PA of rats exposed to combination protocol involving Sugen (VEGF receptor antagonist) and chronic hypoxia, as described in Method section. Quantitative analyses are presented in the upper of the representative images. Using a live/dead cell assay kit (Life Technologies) we demonstrated hypoxia caused no significant effect on HPMEC viability ( Figure IIIA in the online-only Data Supplement). Endothelial cells express 2 isoforms of arginase, Arg1 and Arg2. Hypoxia-induced large increases in Arg2 protein and mRNA levels, as well as in arginase activity ( Figure 2E through 2K ), but Arg1 levels were unchanged by either hypoxia or transient overexpression of Figure 1 . KLF15 (Kruppel-like factor 15) is the major Kruppel-like factor in human pulmonary microvascular endothelial cells (HPMEC) and an important regulator of critical endothelial enzymes-Arg2 (Arginase 2) and eNOS (endothelial nitric oxide). A, Total RNA from HPMEC was converted to cDNA and the relative mRNA expression of KLF15 was determined in quiescent HPMEC using real-time PCR (n=3). B, Cell lysates from HPMEC, human coronary artery endothelial cells (HCAEC), human aortic endothelial cells (HAEC), human aortic smooth muscle cells (HASMC) were subjected to Western blotting with KLF15, eNOS, and β-tubulin antibodies (n=4). Cell lysates from HPMEC overexpressing HA-KLF15 were used as a positive control. C, Total RNA from HPMEC was converted to cDNA and the relative mRNA expression of KLF2, 4, and 15 was determined in quiescent HPMEC using real-time PCR (n=3). *P<0.05 vs KLF15 expression level. D, Lysates of HPMEC with transient overexpression of adenovirally transduced HA-tagged KLF15 or GFP (green fluorescent protein; control) were subjected to immunoblotting with antibodies against Arg2, eNOS, HA, and β-tubulin (n=4). E, Arginase activity was assayed in lysates of HPMEC expressing either GFP (control) or HA-KLF15 (n=6). *P<0.05 vs control (Ad.GFP). F, Media from cultures of HPMEC expressing either GFP (control) or HA-KLF15 was collected at 2, 3, and 4 hours of nonstretch or cyclic stretch conditions, and nitric oxide levels were measured using a Sievers NO analyzer (n=3). *P<0.05 vs control (Ad.GFP and no stretch). DAF-DA fluorescence of HPMEC overexpressed with either GFP (control) or KLF15 (F, lower; n=3). G, HPMEC were transfected with either scrambled siRNA or KLF15 siRNA directed to the coding DNA sequence (CDS) region of KLF15 (No. 7 and No. 9; Qiagen Flexitube) for 48 h, and cell lysates were subjected to immunoblotting with anti-Arg2, anti-KLF15, and β-tubulin antibodies (n=3). *P<0.05 vs Con siRNA. H, Densitometry analysis for G. Figure 2G, 2nd) . Hypoxia failed to reduce eNOS levels in HPMEC ( Figure 2G, 3rd) . These finding strongly suggested that hypoxia-mediated endothelial dysfunction occurred through eNOS uncoupling by upregulated Arg2 levels rather than via either a reduction in eNOS abundance or by Arg1-mediated regulation. To determine whether the zincfinger domain of KLF15 located at the C-terminus is critical for the inhibitory effect of KLF15 on hypoxia-induced Arg2 expression, we studied HPMEC expressing either full-length KLF15 or KLF15 with a truncated C-terminal zinc-finger domain (135 amino acids) via adenoviral delivery, in either hypoxia or normoxia. Induction of Arg2 by hypoxia was completely blocked in HPMEC that ectopically expressed full-length KLF15 whereas the truncated KLF15 had no effect ( Figure 2H ). Further, HPMEC overexpressing KLF15 exhibited ablation of increases in arginase activity in response to hypoxia ( Figure 2I ). In contrast, genetic knockdown of KLF15 by siRNA or shRNA (the effectiveness of Ad-shRNA is shown in Figure XI in the online-only Data Supplement) augmented these responses to hypoxia ( Figure 2J and 2K) . Notably, overexpression of either KLF2 or KLF4 had minimal effects on Arg2 levels in HPMEC under either hypoxic or normoxic conditions ( Figure 2G ).
KLF15 (
KLF15 Overexpression Reverses Arg2-Mediated Effects of Hypoxia on HPMEC NO and ROS Production
To determine whether KLF15 confers protection against hypoxia-induced endothelial dysfunction, we measured NO and superoxide in HPMEC overexpressing either GFP (control) or KLF15 during normoxic and hypoxic conditions. As expected, hypoxia significantly reduced NO and increased ROS production in HPMEC (Figure 2L and 2M; Figure VI in the online-only Data Supplement). Overexpression of KLF15 in HPMEC completely reversed hypoxia-induced attenuation of NO production, and also reduced levels of ROS ( Figure 2L and 2M). Further, HPMEC coexpressing both KLF15 and Arg2 produced about one half as much NO during hypoxia as cells that overexpressed KLF15 alone. This suggests that Arg2 is a critical gene target for KLF15 in hypoxia ( Figure 2L ).
Impairment of Endothelial-Dependent PA Relaxation by Hypoxia Is Ameliorated by KLF15 Overexpression
The significant protection offered by KLF15 against hypoxiainduced increased ROS and reduced NO production in HPMEC prompted us to explore whether these cellular events Figure 2 . KLF15 (Kruppel-like factor 15) is a novel downstream target of hypoxia and its increased expression reverses hypoxia-mediated increases in Arg2 (Arginase 2) expression and reactive oxygen species (ROS) generation and decreased nitric oxide production in human pulmonary microvascular endothelial cells (HPMEC). A, Cell lysates from HPMEC exposed to hypoxia (2% O 2 ) for 24 h were subjected to Western blotting with KLF15, Arg2, and GAPDH antibodies (n=4). Cell lysates from HPMEC overexpressing HA-KLF15 were used as a positive control. B, KLF15 mRNA levels were determined by real-time PCR from HPMEC exposed to hypoxia (2% O 2 ) for 24 h (n=3). n.s P>0.05 vs normoxia. Pulmonary artery from rats subjected to either control or sugen-hypoxia protocol was (C) subjected to immunohistochemical staining with KLF15 antibodies and (D) immunoblotted with KLF15 and β-tubulin antibodies. *P<0.05 vs control (without sugen-hypoxia). E, HPMEC were exposed to hypoxia (2% O 2 ) for 24 h, followed by reoxygenation (21%) for 24 h. Cell lysates were subjected to immunoblotting with antibodies against Arg2 and β-tubulin (n=4). F, HPMEC were exposed to hypoxia (2% O 2 ) for 1, 24, or 48 h and Arg2 mRNA levels were determined by real-time PCR (n=3). *P<0.05 vs normoxia. G, HPMEC with adenovirally mediated overexpression of GFP (green fluorescent protein), KLF2, KLF4, or KLF15 were exposed to either hypoxia or normoxia for 24 h and immunoblotted using antibodies against Arg2, Arg1, eNOS, KLF15, and β-tubulin (n=4). H, Effect of overexpression of either full-length KLF15 or C-terminal truncated KLF15 were determined in hypoxia-induced Arg2 levels (n=4). I, HPMEC cells expressing either GFP (control) or KLF15 were subjected to normoxia or hypoxia, and arginase activity was determined in the cell lysates (n=6). *P<0.05 vs normoxia and $P<0.05 vs GFP overexpressed HPMEC exposed to normoxia. J and K, Quiescent HPMEC expressing GFP (control) were subjected to either normoxia or hypoxia. Additionally, HPMEC with either (J) transfected siRNA (No. 9) or (K) adenoviral-mediated transient knockdown of KLF15 with shRNA were exposed to hypoxia for 24 h, and cell lysates were subjected to immunoblotting with Arg2 and β-tubulin (n=3). L, HPMEC expressing GFP were kept in normoxic conditions and HPMEC expressing GFP, KLF15, or KLF15+Arg2 were exposed to hypoxic conditions. After 24 h of hypoxia, cell culture media was collected and subjected to nitrite measurements using Sievers NO analyzer (n=3). *P<0.05 vs normoxia, #P<0.05 vs hypoxia, and $P<0.05 vs KLF15 overexpressed HPMEC exposed to hypoxia. M, Lysates from HPMEC expressing GFP or KLF15, and in normoxic or hypoxic conditions for 24 h were analyzed for levels of ROS using electron paramagnetic resonance (EPR; n=3). *P<0.05 vs normoxia and #P<0.05 vs GFP overexpressed HPMEC exposed to hypoxia. translated to physiological function at the whole tissue (blood vessel) level. We determined the effects of hypoxia on acetylcholine-dependent relaxation in isolated rat PA segments with intact endothelium. Hypoxia significantly impaired endothelium-dependent relaxation in rat PA ( Figure 3A ) without affecting endothelium-independent relaxation (response to sodium nitroprusside; Figure 3B ). Impaired endothelial-dependent relaxation during hypoxia was almost completely reversed in pulmonary arteries after transduction with adenoviruses encoding KLF15 ( Figure 3A) . KLF15 levels in transduced and nontransduced pulmonary arteries are shown in Figure 3C . To determine whether the adenoviral transduction of the PA explants induced endothelial cell-specific increases in KLF15 expression, PA rings that had the endothelium denuded were studied in parallel with intact vessels. PA segments demonstrated near-total abolition of KLF15 expression after denuding of the vascular endothelium. CD31 serves as a positive control for endothelial cells in this experiment.
KLF15 Acts As a Transcriptional Repressor of Arg2 by Binding to Its Promoter, a Process That Is Reversed by Hypoxia
To explore the mechanism by which KLF15 regulates Arg2, we determined whether transient overexpression of KLF15 in HPMEC altered Arg2 transcription. Using RT-PCR and Arg2-specific primers, we found that Arg2 mRNA expression was downregulated by increased expression of KLF15 ( Figure 4A and 4B) . Importantly, KLF15 overexpression had no effect on ectopic expression of GFP-tagged Arg2 that was controlled by an artificial cytomegalovirus promoter ( Figure 4C ). Additionally, a cycloheximide (inhibitor of de novo protein synthesis) chase assay was performed to determine whether a drop in Arg2 protein levels by KLF15 overexpression was because of shortening of the half-life of Arg2 protein by increased KLF15 expression. As shown in Figure 4 , this seems to be an unlikely explanation ( Figure 4D ). These results suggest that KLF15 is involved in transcriptional, but not translational regulation of Arg2. To determine whether hypoxia regulates Arg2 promoter activity, and whether KLF15 overexpression may modulate this effect, we cotransduced KLF15 and an Arg2 promoterluciferase reporter construct using adenoviruses in HPMEC exposed to normoxia or hypoxia. Luciferase activity generated by the Arg2 promoter was substantially higher in cells grown in hypoxic conditions, and this upregulation of Arg2 promoter activity by hypoxia was absent in HPMEC overexpressing KLF15 ( Figure 4E) .
We next investigated the possibility that KLF15 interacts directly with the Arg2 promoter. We identified 2 consensus KLF-binding sequences-CACCC and GGGTG-within the 2 kb region of the Arg2 promoter that is upstream of the transcription start site ( Figure VIII in the online-only Data Supplement). A ChIP assay, using anti-HA antibody and primers spanning Arg2 promoter segments containing these consensus KLF15-binding sequences, demonstrated that KLF15 binds to both the proximal and the distal regions of the Arg2 promoter ( Figure 4F ). KLF15 binding to the distal promoter region was found to be much higher. Moreover, hypoxia disrupted binding of the Arg2 promoter by KLF15. The greater interaction that we observed between KLF15 and the distal (versus the proximal) Arg2 promoter was consistent with the lower basal promoter activity of the distal Arg2 promoter segment as compared with that of the proximal segment ( Figure 4G ). In response to hypoxia, the activities of both Arg2 promoter segments were enhanced-yet notably, the distal promoter exhibited greater augmentation by hypoxia ( Figure 4H and 4I) . Taken together, these data provide direct evidence that KLF15 is a transcriptional repressor of hypoxiainduced Arg2 expression. , and 10 −5 and #P<0.05 vs hypoxia with all doses of SNP.
KLF15 Is Ubiquitinated and Hypoxia Accelerates Proteasomal Degradation of KLF15
We next investigated mechanism(s) by which hypoxia might downregulate protein (but not mRNA) levels of KLF15 in HPMEC (Figures 2A, 2B , 2E, and 5A). Pretreatment of HPMEC with the proteasomal inhibitor-MG132 not only reversed the effects of hypoxia, but increased KLF15 above control levels ( Figure 5A ). This finding suggested that ubiquitin-directed degradation could play a critical role in hypoxia-mediated decreases in KLF15. Next, FLAG-KLF15 and either GFP alone or HA-ubiquitin were coexpressed in HPMEC. Coimmunoprecipitation with an anti-FLAG antibody and immunoblotting with an anti-HA antibody were then performed. High molecular weight bands (a hallmark of ubiquitinated proteins) were found in lysates from cells coexpressing KLF15 and ubiquitin, but not in cells coexpressing KLF15 and GFP (control plasmid; Figure 5B ). Hypoxia greatly upregulated KLF15 ubiquitination ( Figure 5C ). To determine the physiological relevance of proteasomal degradation of KLF15, the proteasome inhibitor bortezomib was studied in isolated rat PA vasoreactivity in normoxic and hypoxic conditions ( Figure VIIA and VIIB in the onlineonly Data Supplement). Bortezomib pretreatment protected EC-dependent vasorelaxation in hypoxia. These findings suggest that hypoxia enhances ubiquitination of KLF15 and targeting of KLF15 for proteasomal degradation.
KLF15 Is a SUMO-1 Substrate and Is deSUMOylated During Hypoxia
Since KLF15 is a TF that resides primarily in the nucleus, its availability for hypoxia-enhanced ubiquitin-mediated clearance implies that it is first translocated to the cytoplasm. We evaluated whether KLF15 is a SUMO-1 substrate because SUMO-1 modification of proteins have a role in nuclear localization and export. 38 HPMEC were transduced with HA-tagged KLF15 together with one of the following: an active mutant of HPMEC overexpressing either GFP (green fluorescent protein) or KLF15 were subjected to RT-PCR, and mRNA expression was determined using specific primers for (A) Arg2 or (B) KLF15, and 18s (n=3). *P<0.05 vs GFP (control) overexpressed HPMEC. C, Turbo-GFP-tagged Arg2 was coexpressed in HPMEC with either GFP or KLF15, and the cell lysates were subjected to immunoblotting with either t-GFP or Arg2 antibodies (n=4). D, HPMEC overexpressing either GFP or KLF15 were subjected to a cycloheximide (25 µg/mL) chase protocol, and cell lysates were subjected to immunoblotting with Arg2 and β-tubulin antibodies at 0, 2, 4, and 6 h after cycloheximide (n=3). E, HPMEC coexpressing an Arg2 −2 kb promoterluciferase reporter construct (shown at the top) with either KLF15 or GFP were exposed to either normoxic or hypoxic condition and cell lysates were subjected to firefly luciferase activity assay (Promega Dual-Glo luciferase kit; n=3). *P<0.05 vs GFP overexpressed normoxiaexposed HPMEC, $P<0.05 GFP overexpressed hypoxia-exposed HPMEC, #P<0.05 vs GFP overexpressed normoxia-exposed HPMEC, and @P<0.05 vs KLF15 overexpressed normoxia-exposed HPMEC. Renilla luciferase activity from a receptor tyrosine kinase (RTK) promoter adenoviral construct was used as a normalization control. F, HPMEC overexpressing HA-KLF15, and exposed to either normoxia or hypoxia were subjected to a Chromatin Immunoprecipitation (ChIP) assay. HA-antibody and primers spanning the specific regions of Arg2 promoter indicated as A and B were used in the PCR reaction (n=3). *P<0.05 vs Arg2 promoter region #B in normoxic condition, #P<0.05 vs Arg2 promoter region, #A in normoxic condition, and &P<0.05 vs Arg2 promoter region #B in hypoxic condition. G, Firefly luciferase chemiluminescence was determined in quiescent HPMEC expressing an Arg2 −1 kb promoter-luciferase reporter construct that was either 1 kb proximal or distal to the transcription start site. Renilla luciferase activity from an RTK promoter adenoviral construct was used as a normalization control. H and I, HPMEC expressing an Arg2 −1 kb promoter-luciferase reporter construct that was either 1 kb proximal or distal to the transcription start site were exposed to normoxic or hypoxic conditions (24 h), and cell lysates were subjected to firefly luciferase activity assay (Promega Dual-Glo luciferase kit). *P<0.05 vs distal region of Arg2 −2 kb promoter. Renilla luciferase activity from RTK promoter adenoviral construct was used as a normalization control. n=3 for all luciferase activity experiments. *P<0.05 vs normoxia.
GFP-tagged SUMO-1 that has exposed diglycine residues at its C-terminus; an inactive mutant of GFP-tagged SUMO-1 that lacks diglycine residue at the C-terminus making it incapable of forming a disulfide link with its substrate ( Figure IX in the online-only Data Supplement); or GFP alone (control plasmid). As shown in Figure 5D , a higher molecular weight band consistent with SUMO-1+GFP (35 kDa) binding to KLF15 was seen in addition to unmodified HA-KLF15 in lysates from HPMEC coexpressing KLF15 and constitutively active SUMO-1. In contrast, lysates from HPMEC coexpressing KLF15 and inactive SUMO-1 or GFP alone did not exhibit this higher medium wave band. This indicates that the higher HA-KLF15 bands represented covalent conjugation of SUMO-1 to KLF15. We next determined whether hypoxia modulates SUMOylation of KLF15, and found that the amount of SUMOylated KLF15 was indeed attenuated in HPMEC that were exposed to 2 hours of hypoxia, a time consistent with post-translational modification ( Figure 5E ). KLF15 levels in HPMEC coexpressing KLF15 and SUMO were consistently higher than those observed in HPMEC expressing KLF15 and GFP. This prompted us to investigate the effects of SUMOylation on the stability of KLF15 levels. Cycloheximide chase experiments in HPMEC coexpressing either KLF15 and GFP or KLF15 and SUMO-1 demonstrated higher and sustained levels of KLF15 in the presence of SUMO-1 ( Figure 5H ).
KLF15 Primarily Resides in the Nucleus in Quiescent HPMEC and Is Translocated to the Cytoplasm During Hypoxia
To determine whether hypoxia-induced Arg2 expression in HPMEC involves translocation of its transcriptional repressor, KLF15 from nucleus to cytoplasm, we exposed HPMEC expressing HA-KLF15 to hypoxia and monitored KLF15 localization using HA antibody and cell fractionation. In a quiescent HPMEC, KLF15 was found primarily localized to the nucleus, but 2 hours of hypoxia triggered translocation of KLF15 from the nucleus to the cytoplasm ( Figure X in the online-only Data Supplement).
SENP1 Mediates Hypoxia-Dependent Induction of Endothelial Arg2 by deSUMOylating and Affecting Subcellular Localization of KLF15
As SUMOylation is a dynamic process that is catalyzed by SUMO-specific ligases and reversed by SUMO-specific Figure 5 . Hypoxia downregulates KLF15 (Kruppel-like factor 15) levels in human pulmonary microvascular endothelial cells (HPMEC) via enhanced ubiquitin-mediated proteasomal clearance and SUMO-1 (small ubiquitin-like modifiers)-mediated reduced protein stability. A, HPMEC expressing HA-tagged KLF15 were subjected to normoxia or hypoxia with or without MG132 (0.5 μmol/L) for 24 h, and cell lysates were immunoblotted with HA antibody (n=4). B, Lysates from HPMEC coexpressing FLAG-KLF15 and either GFP (green fluorescent protein) or HA-ubiquitin were subjected coimmunoprecipitation experiments with anti-FLAG antibody and immunoblotted with anti-HA antibody (n=4). C, The experimental conditions described in B, above, were executed in normoxia or hypoxia (24 h). D, Lysates from HPMEC that were coexpressing HA-KLF15 and either GFP, GFP-SUMO-1-active, or GFP-SUMO-1-inactive, or GFP-SUMO-1-active or GFP-SUMO-1-inactive alone, were immunoblotted with anti-HA and anti-GFP antibodies (n=4). E, Lysates from HPMEC exposed to normoxia or hypoxia, whereas coexpressing either HA-KLF15 and GFP, or HA-KLF15 and GFP SUMO-1-active were immunoblotted with anti-HA, and anti-GFP antibodies (n=4). F, HPMEC coexpressing HA-KLF15 and either GFP or GFP SUMO-1-active were treated with 25 µg/mL of cycloheximide (CHX), and cell lysates were harvested after 1 h and 2 h of treatment followed by Western blotting with anti-HA and anti-β-tubulin antibodies (n=3).
proteases, we next determined whether the deSUMOylating enzyme, SENP1, and the SUMO-specific ligase, PIASγ-E3 ligase, can modulate KLF15 SUMOylation. As shown in Figure 6A , increased expression of GFP-tagged SENP1 obliterated SUMOylated KLF15, whereas knockdown of SENP1 with shRNA robustly induced KLF15 SUMOylation. This effect seems to be dose-dependent ( Figure 6A ). The effectiveness of our reagents in achieving SENP1 overexpression and knockdown is demonstrated in Figures XII and VIII in the online-only Data Supplement, respectively. Further, increased expression of SUMO-specific ligase PIASγ significantly upregulated SUMO-modified KLF15 ( Figure 6B ). We next determined the effect of SENP1 interference on hypoxiainduced Arg2 expression in HPMEC. As shown in Figure 6C and 6D, increased expression of SENP1 potentiated, whereas silencing SENP1 ( Figure 6D and 6E) significantly attenuated, the Arg2 levels induced by hypoxia. The effectiveness of SENP1 knockdown is demonstrated by dramatic upregulation in global SUMOylation ( Figure 6D, 2nd) . One of the critical consequences of SUMO modification is altered subcellular localization of substrate proteins. 39 To determine whether hypoxia-driven translocation of KLF15 from the nucleus to cytoplasm is mediated by SENP1, we exposed HPMEC cotransduced with HA-KLF15 with either scrambled shRNA or SENP1 shRNA and subject them to either normoxic or hypoxic condition. As shown in Figure 6F and 6G and Figure  XA through XC in the online-only Data Supplement, KLF15 was primarily localized in nucleus in HPMEC transduced with scrambled shRNA that were cultured in normoxic conditions. This changed within 2 hours of exposure to hypoxia, after which a substantial amount of KLF15 was found to be cytosolic (Figure 6F and 6G; Figure XA through XC in the online-only Data Supplement). In contrast, hypoxia failed to decompartmentalize KLF15 from the nucleus to the cytoplasmic fractions in HPMEC that were transduced with SENP1 shRNA ( Figure 6G ). (2) HA-KLF15, GFP-SUMO-1 and increasing concentrations of GFP-SENP-1 cDNA, or (3) HA-KLF15, GFP-SUMO-1 and increasing concentration of SENP1 shRNA adenoviruses were cultured in normoxic or hypoxic conditions for 24 h and cell lysates were immunoblotted with HA antibody (n=4). B, HPMEC expressing either PIASγ E3 ligase or SENP1 shRNA were cotransduced with either HA-KLF15 and GFP or HA-KLF15 and GFP-SUMO-1, and cell lysates were subjected to Western blotting with HA antibodies (n=4). C, HPMEC expressing either GFP or GFP-tagged SENP1 is exposed to normoxia or hypoxia, and cell lysates were immunoblotted with Arg2, SENP1, and β-tubulin antibodies (n=4). D, Densitometry analysis for C. *P<0.05 vs normoxia-exposed HPMEC and #P<0.05 vs hypoxia-exposed HPMEC. E, HPMEC transduced with either control shRNA or SENP1 shRNA were subjected to normoxia or hypoxia, and cell lysates were subjected to Western blotting with Arg2, SUMO-1, and HSP90 (loading control) antibodies (n=4). F, Densitometry analysis for E. #P<0.05 vs normoxia-exposed control shRNA-transfected HPMEC and *P<0.05 vs hypoxia-exposed control shRNA-transfected HPMEC. G, HPMEC subjected to adenoviral cotransduction with either control shRNA and HA-KLF15 or SENP1 shRNA and HA-KLF15 were exposed to either normoxic or hypoxic condition for 24 h and prepared for epifluorescence analysis by fixation with 3.7% paraformaldehyde, and labeling with anti-HA primary antibody and antirat Alexa 465 secondary antibody (n=3). Images were acquired using a confocal microscope (Zeiss LSM 800 laser-scanning). H, Quantification of fluorescent intensity for G presented as a ratio of cytoplasm and nucleus fluorescent intensity. *P<0.05 vs control shRNA-transfected HPMEC exposed to normoxic conditions.
Discussion
Our finding that protein levels of KLF15 are responsive to hypoxia in pulmonary microvascular endothelium provides new insight into transcriptional control of functional homeostasis in the lung microcirculation and its derangement by hypoxia. Transcriptional repression of Arg2 by KLF15 is apparently an important component of the regulatory landscape in normal pulmonary endothelium and prevents the deleterious constellation of consequences that are triggered by induced Arg2 expression; blunted nitric oxide release; increased ROS production; and impaired endothelium-dependent vascular relaxation (Figures 1 through 4) . 8, 36 Further, data presented here delineate the molecular mediation of hypoxia-mediated alteration of subcellular localization of KLF15, and a decrease in its availability in microvascular lung endothelium. These occur by way of SENP1-mediated deSUMOylation of nuclear KLF15, translocation of KLF15 to the cytoplasm, and acceleration of ubiquitin-proteasomemediated degradation and clearance of KLF15 (Figures 5 and  6 ). Diminished KLF15 levels release a transcriptional brake on Arg2, resulting in vascular dysfunction. These mechanisms are summarized in the schematic presented in Figure 7 .
Although pulmonary endothelial function has been implicated heretofore in hypoxia-induced PAH, studies have focused largely on HIF-dependent mechanisms. Thus, PAH developed less often in murine models that were hemizygous for HIF-1α and HIF-2α. 40, 41 Activation of HIF resulting from downregulation of PHD2 (prolyl hydroxylase domaincontaining protein 2) has recently been shown to cause severe HIF-2α-dependent PAH. 15 Efforts to elucidate downstream pathways involved in HIF-2α-dependent PAH have included deletion of pulmonary endothelial Arg1, with resulting attenuation of PAH severity. 13 Importantly, however, Arg2 is the major arginase isoform in endothelial cells, and Arg2 is selectively upregulated over Arg1 by hypoxia as shown in our current study and in previous work by other groups. 8, 13, 41, 42 Further investigation into hypoxia-mediated transcriptional regulation of Arg2 in pulmonary endothelial dysfunction and PAH is therefore warranted.
Our work demonstrates that KLF15 is a novel transcriptional regulator of Arg2 and describes the impact of this interaction in the context of hypoxia. Using ChIP and luciferase reporter assays for Arg2 promoter activity, we have shown that KLF15 directly binds to the Arg2 promoter and represses its transcription (Figure 4) . Hypoxia augmented Arg2 promoter activity, but this upregulation was completely blocked by KLF15 overexpression. Hypoxia increased ROS generation and decreased NO production in HPMEC, and these effects were abrogated by increased expression of KLF15. Ectopic reconstitution of Arg2 blunted the protective effect of KLF15 on NO production, suggesting that Arg2 is a major effector target for KLF15 signaling in HPMEC.
Transcriptional repression of Arg2 by KLF15 is released in hypoxic conditions, as KLF15 is translocated to the cytoplasm by SENP1-mediated reversal of post-translational SUMO-1 conjugation to KLF15. A role for SENP1 in the regulation of responses to hypoxia has been described previously, and the mechanism involves stabilization of HIF-1α through decreased SUMO conjugation and ubiquitin-proteasome-dependent degradation. In the current study, exposure of HPMEC to increasing concentrations of SENP1 shRNA produced dose-dependent effects on KLF15 conjugation, whereas overexpression of SENP1 had the reverse effect. SUMO conjugation is frequently required for nuclear localization, and SUMOylation also regulates nuclear retention of some proteins and TFs. [43] [44] [45] Interestingly, SUMOylation is known to be critical for nuclear localization of another Kruppel-like factor, KLF5. However, the SUMO conjugation site in KLF5 is not conserved in KLF15, and this suggests that the SUMOylation sites in these 2 KLF family members have distinct functions. Further, molecular activation of SENP1 (and hence deSUMOylation) by hypoxia has been shown to occur via the formation of an intermolecular disulfide bond between Cys 603 and Cys 613. 46 These observations are consistent with our findings that KLF15 is deSUMOylated and translocated to the cytoplasm from nucleus in response to hypoxia. As mentioned above, our findings that the overall abundance of KLF15, as well as its nuclear location and stabilization is regulated by SUMO-1 in an oxygen-sensitive manner is not without precedent. HIF-1α abundance and location are primarily regulated by hydroxylation, a process that is O 2 -dependent and targets the protein for ubiquitination and proteasomal degradation (in hypoxic conditions, decreased hydroxylation stabilizes HIF-1α and allows it to bind to HIF-1β allowing transcription of hypoxia-driven target genes). However, emerging evidence suggest that SUMOylation of HIF-1α regulates its activity and abundance. Indeed, Bae et al 47 demonstrated that SUMOylation of Lys391/Lys 477 increases its stability and enhances transcriptional activity by blocking HIF ubiquitination and proteasomal degradation. Moreover, in the context of a rat hypoxic PH model, Jiang et al 48 showed that SUMO-1 seemed to stabilize HIF-1α in response to hypoxia, and upregulated HIF-1-regulated genes. 49 Thus, in the context of both HIF-1 and KLF15, SUMOylation mediated by SUMO-1 seems to stabilize the TFs. In the case of HIF-1, increased SUMOylation is driven by hypoxia and leads to activation of hypoxia-sensitive genes. In contrast, for KLF15, hypoxia leads to destabilization of the transcriptional repression of the deleterious gene Arg2 and results in an increase in Arg2 transcription and downstream vascular endothelial dysfunction.
Tissue-specific function of KLF15 as an epigenetically and metabolically sensitive switch is another intriguing theme of the biology of this TF that emerges from the experiments presented here. This is certainly in keeping with previous groundbreaking work from others in the field, indicating that KLF15 interaction with cell-and tissue-specific nuclear targets cause alteration of cell fate or metabolism in response to autocrine signaling, growth factors, substrate availability, and diurnal cycling in at least 4 diverse contexts. 50, 51 KLF15 has been implicated in endothelin inhibition of BMP (bone morphogenetic protein) endothelial cell precursor-derived regulator and downstream vasculogenesis. 52 Second, SMAD4 and the progesterone receptor trigger KLF15-mediated repression of uterine epithelial growth during mouse embryo implantation. Third, KLF15 interacts with a complex of the liver X receptor, retinoid X receptor, and RIP140 in the murine hepatocyte nucleus in the setting of fasting conditions to drive the transcriptional repression of SREBP-1c with a resulting increase in gluconeogenesis. Fourth, KLF15 has also recently been shown to mediate diurnal metabolic oscillation between catabolic and resting states in rodent cardiomyocytes via transcriptional activation and repression (respectively) of genes regulating ATP availability and other issues in cellular energetics. Our data showing that KLF15 mediates alteration of HPMEC function, as well as rat PA responses in response to ambient oxygen, is, therefore, in keeping with its function in other contexts-KLF15 is a master regulator of homeostatic function in response to environmental stimuli.
Finally, the current work addresses an urgent need for new therapeutic strategies in PH. 53 This need has prompted the PH community to focus on genetic and epigenetic control of inflammation, aberrant growth control, and other sources of cellular dysfunction in the pulmonary circulation. 54, 55 The need for paradigm change in the conceptual framework underlying health care for PH could be facilitated by strategies for the support of KLF15 levels in lung microvasculature via changes in the sensitivity of the SENP1 hypoxia response element, via protection of KLF15 SUMOylation, via inhibition of KLF15 interactions with SENP1, and via blocking KLF15 targeting for ubiquitin-mediated proteasomal clearance. Single and multimodal approaches to KLF15 preservation and augmentation need to be investigated during exposure to hypoxia, and to other environmental stressors that have been implicated in the pathogenesis of PH-including altered estrogen metabolism, mitogen exposure, and oxidative stress. Indeed, endothelial responses and resulting vascular dysfunction in response to each of these perturbations have been shown to involve SUMOylation and deSUMOylation via SENP in models of other diseases. This constellation of data supports the notion that these pathways may be fruitful avenues of approach for PH therapeutics as well. 49, [56] [57] [58] [59] [60] 
